+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

From
Kidney Transplant Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Kidney Transplant Rejection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
End-Stage Renal Disease - Pipeline Insight, 2025 - Product Thumbnail Image

End-Stage Renal Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Acute Liver Failure - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Liver Failure - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hepatitis C Virus Infection- Pipeline Insight, 2025 - Product Thumbnail Image

Hepatitis C Virus Infection- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Cirrhosis- Pipeline Insight, 2025 - Product Thumbnail Image

Cirrhosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 200 Pages
  • Global
From
End-Stage Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

End-Stage Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cyclophilin Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Cyclophilin Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Nephropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Chronic Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Renal Anemia- Pipeline Insight, 2025 - Product Thumbnail Image

Renal Anemia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Lupus Nephritis - Pipeline Insight, 2025 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Hepatitis D - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatitis D - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more